GLP-1 receptor agonist · randomised human trials
What is Semaglutide?
Semaglutide is a peptide medicine that activates the GLP-1 receptor. GLP-1 is a hormone pathway involved in glucose regulation and appetite. A compound name alone does not identify a particular brand, formulation or authorised indication.
How does Semaglutide work?
Semaglutide acts on a receptor pathway rather than physically targeting one body area shown in an illustration. Its metabolic effects are studied through clinical outcomes, not by assuming that a glowing organ in artwork represents a proven benefit. [1]
What does the research show?
The STEP 1 trial, published in 2021, compared semaglutide with placebo alongside lifestyle intervention in 1,961 adults with overweight or obesity who did not have diabetes. It reported greater average weight reduction with semaglutide over 68 weeks. [1]
What the evidence does not establish
The result applies to the population and formulation studied. It does not establish the equivalence of every semaglutide-labelled product. Nausea and diarrhoea were prominent adverse effects reported in the trial.
Safety questions to discuss
Read the exact medicine’s prescribing information with a qualified professional. Health history, interactions and product authenticity are relevant to suitability. [2]
Frequently asked questions
Is semaglutide a GLP-1 medicine?
Yes. It is a GLP-1 receptor agonist.
Does one semaglutide study validate all products bearing that name?
No. Formulation, quality, indication and clinical supervision matter.
Sources and further reading
- STEP 1: Once-Weekly Semaglutide in Adults with Overweight or Obesity, 2021
- SAHPRA: peptide products public information
These are selected sources, not a systematic review. Check publication dates, study methods and the exact substance tested. Artwork does not establish clinical benefit.